Ranjit S. Bindra

Yale New Haven Hospital — United States

Medicine · Health Sciences

43h-index9.3kcitations379works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(114), PARP inhibition in cancer therapy(91), DNA Repair Mechanisms(77), Brain Metastases and Treatment(34), Renal cell carcinoma treatment(29)

Publications379 total

Genomic Characterization of Metastatic Pituitary Neuroendocrine Carcinoma (PITNET) in Two Cases
Journal of Neurological Surgery Part B Skull Base·2026
Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma models
Journal of Clinical Investigation·2025Open Access
Synthesis and Biological Evaluation of Colibactin Derivatives
ACS Chemical Biology·2025Open Access
MGMT-silencing as a novel biomarker in AML: Rational application of a dual alkylator-DNA crosslinker for targeted therapy
Blood·2025Open Access
EXTH-105. Comparative analysis of the MGMT-sensitive interstrand crosslinking agent KL50 based on IDH status in MMR-proficient and -deficient gliomas
Neuro-Oncology·2025Open Access
Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas
Neuro-Oncology·2025
Abstract A100: Systemic targeting of therapeutic RNA into pancreatic tumors via an RNA-binding and cell-penetrating antibody
Cancer Research·2025
DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures
Neuro-Oncology·2025Open Access
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions
2025· 2 citedOpen Access
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Neuro-Oncology·2025· 11 citedOpen Access
Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer
Science Translational Medicine·2025· 4 cited
Abstract 2902: Systematic mapping of chemo-genomic interactions between DNA damaging agents and DNA damage repair genes with targeted CRISPR knockout screening
Cancer Research·2025
Abstract 6291: CellPyAbility: an integrated toolkit for high-throughput cell viability assays and automated analysis
Cancer Research·2025
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (<i>IDH1</i>)– and <i>IDH2</i>‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
Cancer·2025· 7 citedOpen Access
Novel Strategies for Improved Treatment of O6-Methylguanine-DNA Methyltransferase Promoter-Methylated Glioma
Medical Research Archives·2025Open Access
The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma
Neuro-Oncology·2024· 6 citedOpen Access
O6-Guanine Targeting Novel DNA Cross-Linker and ATR Inhibitor Combination for MGMT-Silenced IDH1/2 Mutant Acute Myeloid Leukemia
Blood·2024Open Access
EXTH-23. NEW DNA-CROSSLINKING CHEMOTHERAPY IS EFFECTIVE AGAINST POST-TEMOZOLOMIDE MISMATCH REPAIR-DEFICIENT PATIENT-DERIVED HYPERMUTANT GLIOMAS
Neuro-Oncology·2024Open Access
712 Modeling response to alkylating chemotherapy in a syngeneic model of MMR-deficient glioma
Regular and Young Investigator Award Abstracts·2024Open Access
PARG inhibition induces nuclear aggregation of PARylated PARP1
Structure·2024· 3 cited
page 1 of 19Next →

Frequent Co-authors

Peter M. Glazer(17), Ranjini K. Sundaram(11), Robert G. Bristow(5), Simon N. Powell(5), G. Breuer(4), Alice Meng(4), W. Mark Saltzman(4), Patrick Y. Wen(3), Raymond Y. Huang(3), Parker L. Sulkowski(3), Maria Jasin(3), Brian Shuch(3), Seth Noorbakhsh(3), Aravind Kalathil(3), Anita Hüttner(3), James B. Yu(3), Kenneth B. Roberts(3), Michael Weller(2), Jill S. Barnholtz‐Sloan(2), Susan M. Chang(2)